Symbols / MBOT $2.39 -1.65% Microbot Medical Inc.
MBOT Chart
About
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 160.51M |
| Enterprise Value | 82.78M | Income | -13.14M | Sales | — |
| Book/sh | 1.16 | Cash/sh | 1.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 43 | IPO | — |
| P/E | — | Forward P/E | -7.24 | PEG | — |
| P/S | — | P/B | 2.07 | P/C | — |
| EV/EBITDA | -5.63 | EV/Sales | — | Quick Ratio | 23.04 |
| Current Ratio | 23.33 | Debt/Eq | 1.11 | LT Debt/Eq | — |
| EPS (ttm) | -0.29 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 16:00 | ROA | -21.04% |
| ROE | -32.42% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 67.16M |
| Shs Float | 67.16M | Short Float | 11.38% | Short Ratio | 3.41 |
| Short Interest | — | 52W High | 4.67 | 52W Low | 1.60 |
| Beta | 1.19 | Avg Volume | 2.13M | Volume | 2.71M |
| Target Price | $7.50 | Recom | Strong_buy | Prev Close | $2.43 |
| Price | $2.39 | Change | -1.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.50
Mean price target
2. Current target
$2.39
Latest analyst target
3. DCF / Fair value
$-2.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.39
Low
$5.00
High
$12.00
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-02-10 | init | B. Riley Securities | — → Buy | $5 |
| 2025-12-03 | init | Roth Capital | — → Buy | $6 |
| 2025-11-28 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-10-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-04-16 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-10-18 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-06-06 | reit | HC Wainwright & Co. | — → Buy | $8 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2020-08-18 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2020-01-13 | reit | HC Wainwright & Co. | — → Buy | $26 |
| 2019-12-24 | reit | HC Wainwright & Co. | — → Buy | $12 |
| 2019-07-22 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2018-11-19 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2018-01-31 | init | Ladenburg Thalmann | — → Buy | $2 |
- Microbot takes its U.S.-cleared vascular robot to Needham investors - Stock Titan ue, 14 Apr 2026 18
- Microbot Medical Begins Full U.S. Launch of LIBERTY System - Yahoo Finance Wed, 15 Apr 2026 16
- Microbot Medical's (MBOT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat ue, 14 Apr 2026 12
- MBOT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus ue, 14 Apr 2026 18
- MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company - Stocktwits hu, 05 Mar 2026 08
- Only FDA-cleared single-use endovascular robot expands U.S. rollout - Stock Titan Mon, 13 Apr 2026 12
- Microbot Medical: High-Risk High-Return Stock, Still Hard To Value (NASDAQ:MBOT) - Seeking Alpha hu, 22 Jan 2026 08
- H.C. Wainwright reiterates Microbot Medical stock rating on full market release - Investing.com ue, 14 Apr 2026 12
- Microbot Medical (NASDAQ: MBOT) outlines $39,230,691 at-the-market stock plan - Stock Titan Fri, 10 Apr 2026 21
- Microbot Medical (MBOT) Expands LIBERTY Robot System Release in U.S. - GuruFocus Mon, 13 Apr 2026 15
- Microbot’s LIBERTY robot heads for full US launch despite geopolitical events - Stock Titan ue, 03 Mar 2026 08
- Microbot Medical (NASDAQ: MBOT) to spotlight LIBERTY robotic system FMR - Stock Titan ue, 14 Apr 2026 12
- LIBERTY robot rollout widens for Microbot Medical (NASDAQ: MBOT) - Stock Titan Mon, 13 Apr 2026 12
- Remote vascular surgery robot nears full market release in April - Stock Titan ue, 17 Mar 2026 07
- Microbot Medical (MBOT) files ATM to raise up to $39.2M for LIBERTY® development - Stock Titan Fri, 10 Apr 2026 21
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
14.74
+26.82%
|
11.62
+14.69%
|
10.14
-24.57%
|
13.44
|
| Research And Development |
|
6.28
-5.23%
|
6.63
+15.83%
|
5.72
-26.01%
|
7.74
|
| Selling General And Administration |
|
8.25
+67.59%
|
4.92
+13.99%
|
4.32
-22.65%
|
5.58
|
| General And Administrative Expense |
|
8.25
+67.59%
|
4.92
+13.99%
|
4.32
-22.65%
|
5.58
|
| Salaries And Wages |
|
4.57
+49.92%
|
3.05
+37.99%
|
2.21
-30.43%
|
3.18
|
| Other Gand A |
|
3.28
+129.69%
|
1.43
-14.18%
|
1.66
-0.36%
|
1.67
|
| Other Operating Expenses |
|
0.21
+187.84%
|
0.07
-22.11%
|
0.10
-20.83%
|
0.12
|
| Total Expenses |
|
14.74
+26.82%
|
11.62
+14.69%
|
10.14
-24.57%
|
13.44
|
| Operating Income |
|
-14.74
-26.82%
|
-11.62
-14.69%
|
-10.14
+24.57%
|
-13.44
|
| Total Operating Income As Reported |
|
-14.74
-26.82%
|
-11.62
-17.96%
|
-9.86
+25.80%
|
-13.28
|
| EBITDA |
|
-14.70
-27.41%
|
-11.53
-15.00%
|
-10.03
+24.78%
|
-13.34
|
| Normalized EBITDA |
|
-14.70
-27.41%
|
-11.53
-25.40%
|
-9.20
+32.12%
|
-13.55
|
| Reconciled Depreciation |
|
0.05
-48.35%
|
0.09
-14.15%
|
0.11
+3.92%
|
0.10
|
| EBIT |
|
-14.74
-26.82%
|
-11.62
-14.69%
|
-10.14
+24.57%
|
-13.44
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.83
-486.98%
|
0.21
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.83
-486.98%
|
0.21
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.83
-650.99%
|
0.15
|
| Other Special Charges |
|
—
|
—
|
0.83
+632.05%
|
-0.16
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Pretax Income |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Net Non Operating Interest Income Expense |
|
1.28
+606.04%
|
0.18
-20.18%
|
0.23
+322.22%
|
0.05
|
| Net Interest Income |
|
1.28
+606.04%
|
0.18
-20.18%
|
0.23
+322.22%
|
0.05
|
| Interest Income Non Operating |
|
—
|
—
|
0.28
+424.07%
|
0.05
|
| Interest Income |
|
—
|
—
|
0.28
+424.07%
|
0.05
|
| Other Income Expense |
|
0.32
|
—
|
-0.83
-486.98%
|
0.21
|
| Other Non Operating Income Expenses |
|
0.32
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
-0.06
-185.94%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Net Income From Continuing Operation Net Minority Interest |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Net Income From Continuing And Discontinued Operation |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Net Income Continuous Operations |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Normalized Income |
|
-13.14
-14.85%
|
-11.44
-15.49%
|
-9.91
+25.97%
|
-13.38
|
| Net Income Common Stockholders |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Diluted EPS |
|
-0.29
+60.27%
|
-0.73
+30.48%
|
-1.05
+41.99%
|
-1.81
|
| Basic EPS |
|
-0.29
+60.27%
|
-0.73
+30.48%
|
-1.05
+41.99%
|
-1.81
|
| Basic Average Shares |
|
45.79
+192.69%
|
15.64
+53.38%
|
10.20
+40.49%
|
7.26
|
| Diluted Average Shares |
|
45.79
+192.69%
|
15.64
+53.38%
|
10.20
+40.49%
|
7.26
|
| Diluted NI Availto Com Stockholders |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
—
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of PPE |
|
—
|
0.00
+100.00%
|
-0.00
+60.00%
|
-0.01
|
| Insurance And Claims |
|
0.39
-11.09%
|
0.44
+0.00%
|
0.44
-39.70%
|
0.73
|
| Total Other Finance Cost |
|
-1.28
-606.04%
|
-0.18
+20.18%
|
-0.23
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
8.33
|
| Current Assets |
|
7.92
|
| Cash Cash Equivalents And Short Term Investments |
|
6.38
|
| Cash And Cash Equivalents |
|
2.47
|
| Cash Equivalents |
|
0.00
|
| Cash Financial |
|
2.47
|
| Other Short Term Investments |
|
3.92
|
| Receivables |
|
1.49
|
| Other Receivables |
|
1.49
|
| Loans Receivable |
|
—
|
| Inventory |
|
—
|
| Raw Materials |
|
—
|
| Work In Process |
|
—
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
0.05
|
| Total Non Current Assets |
|
0.41
|
| Net PPE |
|
0.41
|
| Gross PPE |
|
0.90
|
| Accumulated Depreciation |
|
-0.49
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.26
|
| Machinery Furniture Equipment |
|
0.41
|
| Other Properties |
|
—
|
| Leases |
|
0.23
|
| Non Current Prepaid Assets |
|
—
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
3.83
|
| Current Liabilities |
|
3.79
|
| Payables And Accrued Expenses |
|
2.79
|
| Payables |
|
0.36
|
| Accounts Payable |
|
0.36
|
| Current Accrued Expenses |
|
2.43
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.72
|
| Current Debt And Capital Lease Obligation |
|
0.19
|
| Current Capital Lease Obligation |
|
0.19
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Other Current Liabilities |
|
0.08
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
|
| Long Term Capital Lease Obligation |
|
0.04
|
| Stockholders Equity |
|
4.50
|
| Common Stock Equity |
|
4.50
|
| Capital Stock |
|
0.12
|
| Common Stock |
|
0.12
|
| Share Issued |
|
11.71
|
| Ordinary Shares Number |
|
11.71
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
83.88
|
| Retained Earnings |
|
-79.50
|
| Total Equity Gross Minority Interest |
|
4.50
|
| Total Capitalization |
|
4.50
|
| Working Capital |
|
4.13
|
| Invested Capital |
|
4.50
|
| Total Debt |
|
0.23
|
| Capital Lease Obligations |
|
0.23
|
| Net Tangible Assets |
|
4.50
|
| Tangible Book Value |
|
4.50
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.05
-47.80%
|
-8.83
-3.45%
|
-8.53
+26.11%
|
-11.55
|
| Cash Flow From Continuing Operating Activities |
|
-13.05
-47.80%
|
-8.83
-3.45%
|
-8.53
+26.11%
|
-11.55
|
| Net Income From Continuing Operations |
|
-13.14
-14.85%
|
-11.44
-6.55%
|
-10.74
+18.44%
|
-13.17
|
| Depreciation Amortization Depletion |
|
0.05
-48.35%
|
0.09
-14.15%
|
0.11
+3.92%
|
0.10
|
| Depreciation |
|
0.05
-48.35%
|
0.09
-14.15%
|
0.11
+3.92%
|
0.10
|
| Depreciation And Amortization |
|
0.05
-48.35%
|
0.09
-14.15%
|
0.11
+3.92%
|
0.10
|
| Other Non Cash Items |
|
—
|
0.23
-67.32%
|
0.72
+6066.67%
|
-0.01
|
| Stock Based Compensation |
|
1.06
-21.65%
|
1.35
-3.23%
|
1.39
-20.43%
|
1.75
|
| Operating Gains Losses |
|
—
|
—
|
0.00
-60.00%
|
0.01
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.01
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
-60.00%
|
0.01
|
| Change In Working Capital |
|
-1.01
-207.01%
|
0.94
+8663.64%
|
-0.01
+95.18%
|
-0.23
|
| Change In Inventory |
|
-0.58
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
-0.92
-1431.88%
|
0.07
-89.73%
|
0.67
+5069.23%
|
0.01
|
| Change In Payables And Accrued Expense |
|
0.49
-43.30%
|
0.87
+227.82%
|
-0.68
-183.40%
|
-0.24
|
| Investing Cash Flow |
|
-72.38
-4809.43%
|
1.54
-22.10%
|
1.97
+151.43%
|
-3.84
|
| Cash Flow From Continuing Investing Activities |
|
-72.38
-4809.43%
|
1.54
-22.10%
|
1.97
+151.43%
|
-3.84
|
| Net PPE Purchase And Sale |
|
-0.06
-140.00%
|
-0.03
+24.24%
|
-0.03
+60.71%
|
-0.08
|
| Purchase Of PPE |
|
-0.06
-140.00%
|
-0.03
+24.24%
|
-0.03
+60.71%
|
-0.08
|
| Capital Expenditure |
|
-0.06
-140.00%
|
-0.03
+24.24%
|
-0.03
+60.71%
|
-0.08
|
| Net Investment Purchase And Sale |
|
-72.32
-4730.22%
|
1.56
-22.13%
|
2.01
+153.46%
|
-3.75
|
| Purchase Of Investment |
|
-82.93
-1519.65%
|
-5.12
+49.11%
|
-10.06
-168.12%
|
-3.75
|
| Sale Of Investment |
|
10.60
+58.67%
|
6.68
-44.62%
|
12.07
|
0.00
|
| Financing Cash Flow |
|
86.24
+986.69%
|
7.94
+21.01%
|
6.56
+51.67%
|
4.32
|
| Cash Flow From Continuing Financing Activities |
|
86.24
+986.69%
|
7.94
+21.01%
|
6.56
+51.67%
|
4.32
|
| Net Common Stock Issuance |
|
86.24
+986.68%
|
7.94
+21.01%
|
6.56
+51.67%
|
4.32
|
| Proceeds From Stock Option Exercised |
|
0.00
|
0.00
|
—
|
—
|
| Changes In Cash |
|
0.81
+25.39%
|
0.65
+32400.00%
|
-0.00
+99.98%
|
-11.06
|
| Beginning Cash Position |
|
3.16
+25.67%
|
2.52
-0.08%
|
2.52
-81.45%
|
13.58
|
| End Cash Position |
|
3.97
+25.61%
|
3.16
+25.67%
|
2.52
-0.08%
|
2.52
|
| Free Cash Flow |
|
-13.11
-48.06%
|
-8.85
-3.34%
|
-8.57
+26.36%
|
-11.63
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
86.24
+986.68%
|
7.94
+21.01%
|
6.56
+51.67%
|
4.32
|
| Issuance Of Capital Stock |
|
86.24
+986.68%
|
7.94
+21.01%
|
6.56
+51.67%
|
4.32
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-14 View
- 8-K2026-04-13 View
- 8-K2026-04-10 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 8-K2026-03-24 View
- 8-K2026-03-17 View
- 8-K2026-03-10 View
- 8-K2026-03-04 View
- 8-K2026-03-03 View
- 8-K2026-02-24 View
- 8-K2026-02-24 View
- 42026-02-20 View
- 42026-02-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|